Skip to main content

Table 5 The AUROC values of prediction methods for significant fibrosis, advanced fibrosis and cirrhosis in the validation cohort

From: Cytokeratin 18 can help predict liver fibrosis in HCV infected patients with type 2 diabetes mellitus

  Significant fibrosis (F0-1 vs F2-4) Advanced fibrosis (F0-2 vs F3-4) Cirrhosis (F0-3 vs F4)
TE 0.96 (0.92, 0.99) 0.95 (0.92, 0.99) 0.93 (0.87, 0.98)
APRI 0.61 (0.50, 0.73) 0.58 (0.47, 0.68) 0.65 (0.55, 0.75)
FIB-4 0.65 (0.53, 0.76) 0.61 (0.51, 0.71) 0.67 (0.57, 0.77)
TE + CK18 0.97 (0.94, 0.99) 0.95 (0.91, 0.99) 0.93 (0.88, 0.98)
APRI + CK18 0.83 (0.75, 0.92) 0.69 (0.59, 0.79) 0.66 (0.56, 0.77)
FIB-4 + CK18 0.84 (0.77, 0.92) 0.74 (0.65, 0.83) 0.77 (0.69, 0.86)
Comparison of AUROC    
 TE and TE + CK18 .32 .60 .40
 APRI and APRI + CK18 < .001 .19 .89
 FIB-4 and FIB-4 + CK18 < .001 .02 .03
  1. Numbers in parentheses are the 95% confidence interval
  2. AUROC, area under the receiver operating characteristic; APRI, aspartate transaminase-to-platelet ratio; CK18, cytokeratin 18; FIB-4, fibrosis-4 index; TE, transient elastography